Korro Bio (NASDAQ:KRRO) Major Shareholder Buys $2,300,881.00 in Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Scott Sandell acquired 207,100 shares of Korro Bio stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $12.80 on Friday. The firm has a market cap of $120.58 million, a P/E ratio of -1.03 and a beta of 2.98. Korro Bio, Inc. has a 1 year low of $5.20 and a 1 year high of $55.89. The firm’s 50 day moving average price is $10.99 and its 200 day moving average price is $20.18.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 99.63%. The business had revenue of $1.29 million during the quarter, compared to analyst estimates of $0.43 million. As a group, equities analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on KRRO. Raymond James Financial upgraded Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research report on Friday. Cantor Fitzgerald upped their price objective on shares of Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. William Blair raised shares of Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Institutional Investors Weigh In On Korro Bio

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in Korro Bio by 6,185.5% during the third quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock worth $9,542,000 after acquiring an additional 196,079 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Korro Bio in the 3rd quarter valued at about $2,821,000. PNC Financial Services Group Inc. acquired a new position in shares of Korro Bio in the 3rd quarter valued at about $140,000. Wealth Forward LLC purchased a new stake in shares of Korro Bio during the 3rd quarter worth about $240,000. Finally, CWM LLC grew its holdings in shares of Korro Bio by 391.4% during the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock worth $129,000 after purchasing an additional 2,145 shares during the period. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio News Roundup

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.